Chemcon chemicals has given a bad performance in quarter Q2FY23, bith YOY and QOQ. Sales, net profit, Ebita, Ebita margins are all down in the current quarter significantly. In investor presentation, they have mentioned that this is attributed to soft demand from Pharma companies during this quarter. While they are aptly diversifying into other value products, and expansion is on track, it is not possible to understand whether the impact on sales and margins will continue in the coming quarters as well or the demand is likely to improve going forward. Promoters have to come clean on these issues to maintain the fair corporate governance rather than simply keepin patting their back for aggressive expansions that they are boasting off.
| Subscribe To Our Free Newsletter |
